Literature DB >> 29350504

Age-related changes of superoxide dismutase activity in patients with schizophrenia.

Vladimir V Đorđević, Dušan Lazarević, Vladan Ćosić, Marinela Knežević, Vidosava B Đorđević.   

Abstract

Background/Aim: Superoxide dismutase (SOD) is the critical enzyme in the detoxification of superoxide radicals because those are the first species produced in the majority of biological free radical producing reactions. Inconsistent data are present about SOD activity in patients with schizophrenia. Numerous studies have shown that SOD has been elevated in chronic schizophrenic patients. However, decreased SOD activity was found in neuroleptic naïve, first episode schizophrenic patients, in chronic-medicated patients and in chronic-unmedicated patients. The aim of this study was to examine which of the following factors including age, gender, the onset of the disease, the duration, the number of episodes, heredity, psychopathologic symptoms and drug treatment could affect erythrocyte SOD activity in patients with schizophrenia.
Methods: This study included 68 consecutive patients with schizophrenia (29 males and 39 females) ranging in age from 18 to 61 years, divided into two age groups (<34 years and >34 years). SOD activity was measured in erythrocyte hemolyzates by Ransod commercially available test.
Results: In the group of patients younger than 34 years SOD levels were significantly higher (1381±273 U/gHb, p=0.038) compared to the levels of the older group (1231±206 U/gHb). Gender and heredity did not induce any significant difference in SOD activity between younger and older subgroups. A significant difference in enzyme activity was found between the younger and older subgroups having the onset of the disease after 24 years of age (1408±217 U/gHb vs. 1252±213 U/gHb, p=0.031). The patients of the younger group who had more than one psychotic episode had significantly higher SOD activity (1492±298 U/gHb; p=0.009) than those who had only one episode (1256±177 U/gHb), as well as than the older subgroup with more than one episode (1253±231 U/gHb; p=0.014). Although the duration of the disease did not induce any significant difference in enzyme activity between younger and older subgroups, a significant negative correlation was obtained between SOD activity and the duration of the disease (r=-0.511, p<0.01). No significant differences were found in SOD activity between the subgroups with different PANSS scores. First generation antipsychotics were associated with elevated enzyme activity in both groups. Simultaneous treatment of patients with first generation antipsychotics and second generation antipsychotics induced a significant decrease in SOD activity in the younger group.
Conclusion: Our results show that erythrocyte SOD activity is increased in the early phase of schizophrenia and that depends on age of onset of the disease, the number of psychotic episodes, the duration of the disease and medical treatment.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 29350504     DOI: 10.2298/VSP141202142D

Source DB:  PubMed          Journal:  Vojnosanit Pregl        ISSN: 0042-8450            Impact factor:   0.168


  5 in total

Review 1.  Recent Reports on Redox Stress-Induced Mitochondrial DNA Variations, Neuroglial Interactions, and NMDA Receptor System in Pathophysiology of Schizophrenia.

Authors:  Narasimha M Beeraka; Marco F Avila-Rodriguez; Gjumrakch Aliev
Journal:  Mol Neurobiol       Date:  2022-01-27       Impact factor: 5.590

2.  Association of antioxidant deficiency and the level of products of protein and lipid peroxidation in patients with the first episode of schizophrenia.

Authors:  Anna Sergeevna Piatoikina; Anastasia Alexandrovna Lyakhova; Ilya Vladimirovich Semennov; Tatyana Vladimirovna Zhilyaeva; Olga Vladimirovna Kostina; Ekaterina Sergeevna Zhukova; Tatyana Grigorievna Shcherbatyuk; Evgeny Dmitrievich Kasyanov; Anna Sergeevna Blagonravova; Galina Elevna Mazo
Journal:  J Mol Neurosci       Date:  2021-08-19       Impact factor: 3.444

3.  Targeting D-Amino Acid Oxidase (DAAO) for the Treatment of Schizophrenia: Rationale and Current Status of Research.

Authors:  Chien-Yi Kuo; Chieh-Hsin Lin; Hsien-Yuan Lane
Journal:  CNS Drugs       Date:  2022-10-04       Impact factor: 6.497

4.  Increased Markers of Oxidative Stress and Positive Correlation Low-Grade Inflammation with Positive Symptoms in the First Episode of Schizophrenia in Drug-Naïve Patients.

Authors:  Ewa Dudzińska; Kinga Szymona; Jacek Bogucki; Wojciech Koch; Ewelina Cholewińska; Robert Sitarz; Katarzyna Ognik
Journal:  J Clin Med       Date:  2022-05-02       Impact factor: 4.964

5.  Interrelationships Between BDNF, Superoxide Dismutase, and Cognitive Impairment in Drug-Naive First-Episode Patients With Schizophrenia.

Authors:  Mei Hong Xiu; Zezhi Li; Da Chun Chen; Song Chen; Maile E Curbo; Hanjing Emily Wu; Yong Sheng Tong; Shu Ping Tan; Xiang Yang Zhang
Journal:  Schizophr Bull       Date:  2020-12-01       Impact factor: 9.306

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.